Download PDF
Rofo 2017; 189(03): 219-227
DOI: 10.1055/s-0042-115817
Review
© Georg Thieme Verlag KG Stuttgart · New York

Treatment Failure After Image-Guided Percutaneous Radiofrequency Ablation (RFA) of Renal Tumors – A Systematic Review with Description of Type, Frequency, Risk Factors and Management

Therapieversagen nach bildgeführter perkutaner Radiofrequenzablation (RFA) von Nierentumoren – eine systematische Übersicht mit Beschreibung von Typ, Häufigkeit, Risikofaktoren und Management
Dominik Vollherbst
1   Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany
,
Robert Bertheau
2   Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
,
Hans-Ulrich Kauczor
2   Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
,
Boris Alexis Radeleff
2   Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
,
Philippe L. Pereira
3   Clinic for Radiology, Minimally-invasive Therapies and Nuclear Medicine, SLK-Kliniken, Heilbronn, Germany
,
Christof-Matthias Sommer
2   Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
4   Clinic for Diagnostic and Interventional Radiology, Klinikum Stuttgart, Stuttgart, Germany
› Author Affiliations
Further Information

Publication History

18 May 2016

06 August 2016

Publication Date:
14 September 2016 (online)

Also available at
   Permissions and Reprints

Corrected by:

Erratum: Treatment Failure After Image-Guided Percutaneous Radiofrequency Ablation (RFA) of Renal Tumors – A Systematic Review with Description of Type, Frequency, Risk Factors and ManagementRofo 2017; 189(03): e1-e1
DOI: 10.1055/s-0035-1567133

Abstract

Background Radiofrequency ablation (RFA) is an established treatment for small renal tumors. The objective of this review is to systematically assess the type, frequency, risk factors and management of treatment failure after image-guided percutaneous RFA of renal tumors.

Method 10 studies (967 patients, 1033 tumors) with a mean/median follow-up of ≥ 30 months were systematically identified and analyzed.

Results and Conclusion Image-guided percutaneous RFA of localized renal tumors is very effective. The most common type of treatment failure is residual unablated tumor (5.9 %), followed by local tumor progression (4.7 %). De novo tumors in the kidneys occur in 1.3 % of cases and extra-renal metastases in 2.0 %. Local tumor progression, de novo tumors in the kidneys and extra-renal metastases occur predominantly later than 12 months after initial RFA. Tumor size > 3 cm and central tumor location are the major risk factors for treatment failure. In the case of treatment failure, repeated RFA shows high success rates (86.3 % for residual unablated tumors and 87.5 % for local tumor progression).

Key Points:

  • Treatment failure can be subdivided into residual unablated tumor and local tumor progression.

  • Residual unablated tumor occurs in 5.9 % of cases.

  • Local tumor progression occurs in 4.7 % of cases.

  • Tumor size and location are the major risk factors for treatment failure.

  • Repeated RFA is effective and commonly used for management.

Citation Format

  • Vollherbst D, Bertheau R, Kauczor H et al. Treatment Failure After Image-Guided Percutaneous Radiofrequency Ablation (RFA) of Renal Tumors – A Systematic Review with Description of Type, Frequency, Risk Factors and Management. Fortschr Röntgenstr 2017; 189: 219 – 227

Zusammenfassung

Hintergrund Die Radiofrequenzablation (RFA) ist ein etabliertes Verfahren zur Behandlung von kleinen Nierentumoren. Das Ziel dieser Übersicht ist die systematische Erfassung von Häufigkeit, Typ, Risikofaktoren und Management von Therapieversagen nach bildgeführter perkutaner RFA von Nierentumoren.

Methode Zehn Studien (967 Patienten, 1033 Tumoren) mit einem mittleren/medianen Beobachtungszeitraum von ≥ 30 Monaten wurden systematisch identifiziert und ausgewertet.

Ergebnisse und Schlussfolgerung Die bildgeführte perkutane RFA ist eine sehr effektive Technik zur Behandlung von umschriebenen Nierentumoren. Der residuelle nicht-abladierte Tumor ist der häufigste Typ des Therapieversagens (5,9 %), gefolgt von lokalem Tumorprogress (4,7 %). De-novo-Nierentumoren treten in 1,3 % und extrarenale Metastasen in 2,0 % der Fälle auf. Lokaler Tumorprogress, de-novo-Nierentumoren und extrarenale Metastasen treten vorwiegend später als 12 Monate nach initialer RFA auf. Eine Tumorgröße > 3 cm und eine zentrale Tumorlokalisation sind die Hauptrisikofaktoren für das Therapieversagen. Im Falle eines Therapieversagens zeigt die erneute RFA eine hohe Erfolgsrate (86,3 % für residuelle nicht-abladierte Tumoren und 87,5 % für lokalen Tumorprogress).

Kernaussagen:

  • Therapieversagen kann in residuelle nicht-abladierte Tumoren und lokalen Tumorprogress unterteilt werden.

  • Residuelle nicht-abladierte Tumoren treten in 5,9 % der Fälle auf.

  • Lokaler Tumorprogress tritt in 4,7 % der Fälle auf.

  • Tumorgröße und Tumorlokalisation sind Hauptrisikofaktoren für das Therapieversagen.

  • Die erneute RFA ist effektiv und wird regelmäßig durchgeführt.

Key words

radiofrequency ablation (RFA, RF ablation) - tumor ablation (TA) - image-guided - renal tumor - kidney
 

  • References

  • 1 Sommer CM. Stampfl U. Kauczor HU. et al. Percutaneous radiofrequency ablation of renal tumors: update 2015. Urologe A 2015; 54: 219-230
    CrossrefPubMedGoogle Scholar
  • 2 Psutka SP. Feldman AS. McDougal WS. et al. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol 2013; 63: 486-492
    CrossrefPubMedGoogle Scholar
  • 3 Wah TM. Irving HC. Gregory W. et al. Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 2014; 113: 416-428
    CrossrefPubMedGoogle Scholar
  • 4 Takaki H. Yamakado K. Soga N. et al. Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma. Jpn J Radiol 2010; 28: 460-468
    CrossrefPubMedGoogle Scholar
  • 5 Turna B. Kaouk JH. Frota R. et al. Minimally invasive nephron sparing management for renal tumors in solitary kidneys. J Urol 2009; 182: 2150-2157
    CrossrefPubMedGoogle Scholar
  • 6 Zagoria RJ. Traver MA. Werle DM. et al. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. Am J Roentgenol 2007; 189: 429-436
    CrossrefPubMedGoogle Scholar
  • 7 Salas N. Ramanathan R. Dummett S. et al. Results of radiofrequency kidney tumor ablation: renal function preservation and oncologic efficacy. World J Urol 2010; 28: 583-591
    CrossrefPubMedGoogle Scholar
  • 8 Zagoria RJ. Pettus JA. Rogers M. et al. Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma. Urology 2011; 77: 1393-1397
    CrossrefPubMedGoogle Scholar
  • 9 McDougal WS. Gervais DA. McGovern FJ. et al. Long-term followup of patients with renal cell carcinoma treated with radio frequency ablation with curative intent. J Urol 2005; 174: 61-63
    CrossrefPubMedGoogle Scholar
  • 10 Liberati A. Altman DG. Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700
    CrossrefPubMedGoogle Scholar
  • 11 Downs SH. Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377-384
    CrossrefPubMedGoogle Scholar
  • 12 Ahmed M. Technology Assessment Committee of the Society of Interventional R. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update: supplement to the consensus document. J Vasc Interv Radiol 2014; 25: 1706-1708
    CrossrefPubMedGoogle Scholar
  • 13 Ferakis N. Bouropoulos C. Granitsas T. et al. Long-term results after computed-tomography-guided percutaneous radiofrequency ablation for small renal tumors. J Endourol 2010; 24: 1909-1913
    CrossrefPubMedGoogle Scholar
  • 14 Balageas P. Cornelis F. Le Bras Y. et al. Ten-year experience of percutaneous image-guided radiofrequency ablation of malignant renal tumours in high-risk patients. Eur Radiol 2013; 23: 1925-1932
    CrossrefPubMedGoogle Scholar
  • 15 Iannuccilli JD. Dupuy DE. Beland MD. et al. Effectiveness and safety of computed tomography-guided radiofrequency ablation of renal cancer: a 14-year single institution experience in 203 patients. Eur Radiol 2015; DOI: 10.1007/s00330-015-4006-7.
    PubMedGoogle Scholar
  • 16 Forauer AR. Dewey BJ. Seigne JD. Cancer-free survival and local tumor control after impendence-based radiofrequency ablation of biopsy-proven renal cell carcinomas with a minimum of 1-year follow-up. Urol Oncol 2014; 32: 869-876
    CrossrefPubMedGoogle Scholar
  • 17 Pieper CC. Fischer S. Strunk H. et al. Percutaneous CT-Guided Radiofrequency Ablation of Solitary Small Renal Masses: A Single Center Experience. Rofo 2015; 187: 577-583
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Duan XH. Li YS. Han XW. et al. C-arm CT-guided renal arterial embolisation followed by radiofrequency ablation for treatment of patients with unresectable renal cell carcinoma. Clin Radiol 2016; 71: 79-85
    CrossrefPubMedGoogle Scholar
  • 19 Winokur RS. Pua BB. Madoff DC. Role of combined embolization and ablation in management of renal masses. Seminars in interventional radiology 2014; 31: 82-85
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Arima K. Yamakado K. Kinbara H. et al. Percutaneous radiofrequency ablation with transarterial embolization is useful for treatment of stage 1 renal cell carcinoma with surgical risk: results at 2-year mean follow up. International journal of urology: official journal of the Japanese Urological Association 2007; 14: 585-590 ; discussion 590
    CrossrefPubMedGoogle Scholar
  • 21 Tsui KH. van Ophoven A. Shvarts O. et al. Nephron-sparing surgery for renal cell carcinoma. Rev Urol 1999; 1: 216-225
    PubMedGoogle Scholar
  • 22 Sung HH. Park BK. Kim CK. et al. Comparison of percutaneous radiofrequency ablation and open partial nephrectomy for the treatment of size- and location-matched renal masses. Int J Hyperthermia 2012; 28: 227-234
    CrossrefPubMedGoogle Scholar
  • 23 Thompson RH. Atwell T. Schmit G. et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015; 67: 252-259
    CrossrefPubMedGoogle Scholar
  • 24 Grimaldi G. Reuter V. Russo P. Bilateral non-familial renal cell carcinoma. Ann Surg Oncol 1998; 5: 548-552
    CrossrefPubMedGoogle Scholar
  • 25 Kyung YS. You D. Kwon T. et al. The type of nephrectomy has little effect on overall survival or cardiac events in patients of 70 years and older with localized clinical t1 stage renal masses. Korean J Urol 2014; 55: 446-452
    CrossrefPubMedGoogle Scholar
  • 26 Huang WC. Levey AS. Serio AM. et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7: 735-740
    CrossrefPubMedGoogle Scholar
  • 27 Weight CJ. Larson BT. Fergany AF. et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol 2010; 183: 1317-1323
    CrossrefPubMedGoogle Scholar
  • 28 Park BK. Kim CK. Park SY. et al. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease: indications, techniques, complications, and outcomes. Acta Radiol 2013; 54: 418-427
    CrossrefPubMedGoogle Scholar
  • 29 Nao T. Shimamoto T. Karashima T. et al. Clinical study on patients with renal-cell carcinoma accompanied with Von Hippel-Lindau disease treated with radiofrequency ablation. Hinyokika Kiyo 2014; 60: 415-420
    PubMedGoogle Scholar
  • 30 Krokidis M. Spiliopoulos S. Jarzabek M. et al. Percutaneous radiofrequency ablation of small renal tumours in patients with a single functioning kidney: long-term results. Eur Radiol 2013; 23: 1933-1939
    CrossrefPubMedGoogle Scholar
  • 31 Brookman-May S. May M. Shariat SF. et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol 2013; 64: 472-477
    CrossrefPubMedGoogle Scholar
  • 32 Buti S. Bersanelli M. Sikokis A. et al. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 2013; 24: 535-554
    PubMedGoogle Scholar
  • 33 Borghesi M. Brunocilla E. Volpe A. et al. Active surveillance for clinically localized renal tumors: An updated review of current indications and clinical outcomes. Int J Urol 2015; 22: 432-438
    CrossrefPubMedGoogle Scholar
  • 34 Cornelis F. Balageas P. Le Bras Y. et al. Radiologically-guided thermal ablation of renal tumours. Diagn Interv Imaging 2012; 93: 246-261
    CrossrefPubMedGoogle Scholar
  • 35 Haddad RL. Patel MI. Vladica P. et al. Percutaneous radiofrequency ablation of small renal tumors using CT-guidance: a review and its current role. Urol J 2012; 9: 629-638
    PubMedGoogle Scholar
  • 36 Georgiades C. Rodriguez R. Renal tumor ablation. Tech Vasc Interv Radiol 2013; 16: 230-238
    CrossrefPubMedGoogle Scholar
  • 37 Castaneda CV. Danzig MR. Finkelstein JB. et al. The natural history of renal functional decline in patients undergoing surveillance in the DISSRM registry. Urol Oncol 2015; 33: 166 e117-e120
    PubMedGoogle Scholar
  • 38 Parker PA. Alba F. Fellman B. et al. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol 2013; 63: 1122-1127
    CrossrefPubMedGoogle Scholar
  • 39 Hwang EC. Yu HS. Kwon DD. Small renal masses: surgery or surveillance. Korean J Urol 2013; 54: 283-288
    CrossrefPubMedGoogle Scholar
  • 40 Shin BJ. Chick JF. Stavropoulos SW. Contemporary Status of Percutaneous Ablation for the Small Renal Mass. Curr Urol Rep 2016; 17: 23
    CrossrefPubMedGoogle Scholar
  • 41 El Dib R. Touma NJ. Kapoor A. Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. BJU Int 2012; 110: 510-516
    CrossrefPubMedGoogle Scholar
  • 42 Atwell TD. Schmit GD. Boorjian SA. et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. Am J Roentgenol 2013; 200: 461-466
    CrossrefPubMedGoogle Scholar
  • 43 Pirasteh A. Snyder L. Boncher N. et al. Cryoablation vs. radiofrequency ablation for small renal masses. Acad Radiol 2011; 18: 97-100
    CrossrefPubMedGoogle Scholar
  • 44 Regier M. Chun F. Thermal Ablation of Renal Tumors: Indications, Techniques and Results. Dtsch Arztebl Int 2015; 112: 412-418
    PubMedGoogle Scholar
  • 45 Higgins LJ. Hong K. Renal Ablation Techniques: State of the Art. Am J Roentgenol 2015; 205: 735-741
    CrossrefPubMedGoogle Scholar